Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations UNR844 - Reduction of disulfide bonds Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) READER (CUNR844A2022) Presbyopia Phase 2B 225 Characterize the dose response relationship among UNR844 doses 0 mg/mL, 5 mg/mL, 13.3 mg/mL, 23 mg/mL and 30 mg/mL dosed twice-daily after Month 3 of dosing. Change from baseline in Binocular distance-corrected near visual acuity at 40 cm at Month 3. 1:1 randomization - UNR844 0 mg/mL, 5 mg/mL, 13.3 mg/mL, 23 mg/mL and 30 mg/mL dosed twice-daily for three months Presbyopic participants aged 45 to 55 years Q3 2022: Interim analysis (Primary endpoint) - when all patients have completed the 3 months treatment period Q4 2022: Interim analysis - when 60% of patients have completed 6 months of post treatment follow-up Q2 2023: Final analysis -Study completion (all patients have completed 9 months pots treatment period) Publication TBD 126 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation